• Article, Blog

Pharmaceutical Equipment Qualification & Control System Validation

  • 15 Minutes

How to Qualify Process Equipment and Control Systems in Pharmaceutical Manufacturing

In pharmaceutical manufacturing, process equipment and control systems are not simply operational assets, they are directly linked to product quality, patient safety, and GMP compliance. They govern critical process parameters, generate the quality records regulators rely on, and provide the evidence that each batch was manufactured under controlled conditions. Throughout, this guidance aligns with the regulatory frameworks that govern pharmaceutical equipment and systems: EU GMP Annex 15 (qualification and validation), EU GMP Annex 11 (computerised systems) and FDA 21 CFR Part 11 (electronic records and data integrity), and the GAMP 5 framework for a risk-based, lifecycle approach to computerised systems. 

 

As manufacturing becomes more automated and digitally connected, robust qualification and validation are no longer optional. They are core pillars of any mature pharmaceutical quality system. 

 

This guide sets out a practical framework for qualifying process equipment and control systems from defining user requirements through to maintaining the validated state over the system lifecycle. 

1. Start With GMP-Relevant User Requirements

Every effective qualification begins with a well-written User Requirement Specification (URS). In a pharmaceutical context, the URS must go beyond functional performance. It should capture the GMP expectations the equipment or system must meet from day one. 

 

Think of the URS as the recipe for your manufacturing process. If the recipe is incomplete or ambiguous, the result is unpredictable. Equally, if your requirements are vague, your qualification testing will not reliably address the things that matter most for quality. 

What to include in a URS for process equipment

  • Intended use and product contact parts 
  • Materials of construction and cleaning requirements 
  • Operating ranges and critical process parameters (CPPs) 
  • Utilities, calibration, and maintenance requirements 
  • Safety features and environmental controls 

What to include in a URS for control systems

  • User access levels and role-based permissions 
  • Audit trail requirements 
  • Electronic records and data retention 
  • Alarm management and interlocks 
  • Recipe management and version control 
  • System interfaces, backup, and recovery 
  • Cybersecurity and network controls 

The most important rule: requirements must be clear and testable. A statement such as ‘the system shall be compliant’ is insufficient. A strong requirement defines specific expectations. For example, that user access is role-restricted, that audit trails are secure and complete, that recipes require authorised approval before use, and that electronic records are protected against unauthorised amendment. 

 

Key principle: Vague requirements produce unreliable qualification. Invest time in writing precise, testable specifications before you begin. 

2. Apply a Risk-Based Approach Focused on Product Quality

Not all functions in a pharmaceutical system carry the same risk. Some have a direct impact on critical quality attributes (CQAs) or patient safety. Others support routine operation without a direct quality consequence. A risk-based approach lets you direct validation effort towards the areas where it has the greatest impact, and where regulators expect the most rigour. 

High-priority functions typically include

  • Sterilisation cycle parameters (temperature, time, pressure) 
  • Cleanroom pressure differentials and HVAC performance 
  • Filling line speed and dosing accuracy 
  • Clean-in-place (CIP) cycle parameters 
  • Data integrity controls for batch records used in release decisions 

A basic status indicator or non-critical display screen may require a proportionally lower level of testing. The objective is not to test less overall, it is to test intelligently, concentrating verification effort where risk is highest. 

Risk assessment should consider

  • Impact on product quality and patient safety 
  • Process criticality and automation complexity 
  • Data integrity exposure 
  • Contamination risk 
  • Supplier reliability and regulatory precedent 

Critically, risk assessment should not sit with engineering alone. It works best as a cross-functional activity involving quality assurance, validation, production, automation, and IT. Equipment performance, software logic, cleaning effectiveness, and data reliability are often interdependent and the people closest to those disciplines are best placed to identify where the real risks lie. 

3. Integrate Equipment Qualification and Control System Validation

One of the most common gaps in pharmaceutical qualification programmes is treating equipment and its control system as separate activities. In practice, they cannot be fully decoupled. The equipment provides the physical capability; the control system governs how the process is executed, monitored, recorded, and protected. 

 

An autoclave may be mechanically sound, but if the control system does not correctly manage sterilisation parameters, alarms, batch records, or user access, the process is not under control. The same applies to reactors, filling lines, HVAC systems, purified water systems, and cleaning systems. 

DQ, IQ, OQ, and PQ: what each phase should cover

  • Design Qualification (DQ): Confirm that the proposed design of the equipment or system is suitable for the intended purpose and meets user requirements before procurement or build. 
  • Installation Qualification (IQ): Confirm that equipment, utilities, instruments, software, network connections, and documentation are installed in accordance with approved specifications. 
  • Operational Qualification (OQ): Challenge operating ranges, alarms, interlocks, security settings, recipes, audit trails, and failure conditions. Verify that the system behaves as specified across its full operating envelope. 
  • Performance Qualification (PQ): Demonstrate that the integrated system performs consistently under realistic manufacturing conditions with actual products, operators, and workflows. 

Data integrity, a particular focus for pharmaceutical control systems

For any system that generates data used in batch release, deviation investigations, cleaning validation, environmental monitoring, or quality decisions, data integrity is non-negotiable. Electronic records must be attributable, legible, contemporaneous, original, and accurate (ALCOA+). They must be protected against unauthorised changes and supported by complete, secure audit trails. 

 

Qualification teams should specifically challenge: who can access the system and at what privilege level; whether audit trail entries are complete and cannot be disabled; whether records are backed up, recoverable, and stored for the required retention period; and whether the system is protected against external access or tampering. 

4. Maintain the Validated State Throughout the System Lifecycle

Qualification is not complete when the final report is approved. Sensors are replaced. Software versions are updated. PLC logic is modified. Recipes change. New products and processes are introduced. Each of these events has the potential to affect the validated state of the system. 

 

A robust change control process is essential to evaluate the impact of each change before it is implemented, and to determine whether requalification or additional testing is required. Periodic review provides a structured opportunity to confirm that the system remains in a validated state and continues to meet its intended purpose.

Ongoing lifecycle activities to maintain validation

  • Change control, evaluate impact before implementation 
  • Calibration and preventive maintenance schedules 
  • Deviation management and CAPA (Corrective and Preventive Action) follow-through 
  • Periodic review of system performance and qualification status 
  • Supplier audits where software or firmware is maintained externally 

Practical Summary: Qualification Essentials at a Glance

Tabla Fases
Phase Key focus areas
URS Intended use, CPPs, GMP controls, data integrity, access management
Risk Assessment CQA impact, patient safety, data integrity, contamination, automation complexity
IQ Installation conformance, software version, network, documentation
OQ Operating ranges, alarms, interlocks, recipes, audit trails, failure modes
PQ Real-world performance, process consistency, operator interaction
Lifecycle Change control, calibration, PM, periodic review, deviation management

Frequently Asked Questions

What is pharmaceutical equipment qualification?

Pharmaceutical equipment qualification is the documented process of verifying that process equipment is installed correctly, operates within specified parameters, and consistently performs its intended function under actual manufacturing conditions. It typically encompasses Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ), underpinned by a risk-based approach and a GMP-relevant User Requirement Specification. 

What is the difference between equipment qualification and control system validation?

Equipment qualification focuses on the physical assets, confirming correct installation, operating performance, and consistent process output. Control system validation (also known as CSV) focuses on the software and automated control components that govern how a process is executed, monitored, and recorded. In pharmaceutical manufacturing, both must be addressed together: the equipment delivers the physical capability, whilst the control system determines whether that capability is executed and documented in a GMP-compliant manner. 

What does a GMP User Requirement Specification (URS) need to include?

A GMP URS should cover intended use, product contact materials and cleaning requirements, critical process parameters, operating ranges, utilities, calibration, maintenance, and safety features. For control systems, it must also address user access levels, audit trails, electronic records, alarm management, recipe control, data retention, backup and recovery, and cybersecurity controls. All requirements should be written in a clear, testable format. 

How does a risk-based approach work in pharmaceutical qualification?

A risk-based approach prioritises validation effort according to the potential impact on critical quality attributes (CQAs) and patient safety. Functions that directly affect product quality such as sterilisation parameters, clean-in-place cycles, or data integrity controls require thorough verification and strict acceptance criteria. Functions with no direct quality impact may be addressed with lighter testing. Risk assessment should be cross-functional, involving quality assurance, validation, production, automation, engineering and IT. 

What is data integrity in the context of control system validation?

Data integrity in pharmaceutical control system validation refers to the assurance that electronic records are complete, accurate, consistent, attributable, and protected against unauthorised change. Regulators expect systems to generate trustworthy data that supports batch release, deviation investigations, and quality decisions. Key controls include role-based access, secure and complete audit trails, system backup and recovery, and data retention in line with regulatory requirements. 

When does a qualified system need to be requalified?

Requalification may be required following changes to equipment, software, PLC logic, recipes, operating ranges, or site infrastructure. A robust change control process evaluates the impact of each change and determines whether additional qualification activities are needed. Periodic review, conducted at a frequency defined by the equipment’s risk assessment, provides a further check that the system remains in a validated state. Requalification frequency typically ranges from annually for high-risk systems such as HVAC and autoclaves, to every 3 to 5 years for lower-criticality equipment. 

Building Confidence Through Qualification

Qualifying process equipment and control systems in pharmaceutical manufacturing is about far more than passing a series of technical tests. Done well, it builds justified confidence that your processes are controlled, your data is trustworthy, and your products are consistently safe and effective. 

 

A strong qualification strategy, grounded in clear user requirements, informed by risk, and maintained through disciplined lifecycle management, supports GMP compliance, improves operational reliability, and protects patients.  

Need independent support with equipment qualification or control system validation?

Rephine’s consultants bring deep GxP expertise to every project from URS development and risk assessment through to DQ/IQ/OQ/PQ execution and lifecycle management. Get in touch to discuss how we can support your programme. 

Marc Bonet Web

Marc Bonet

Validation & GMP Consultant

About the Author:

Marc Bonet is one of us Validation & GMP Consultant at Rephine, a global leader in GxP compliance and quality assurance.

 

We don’t just deliver audits or consultancy services — we partner with clients at every stage of their quality journey, offering end-to-end solutions that empower confidence and compliance.

 

With over 25 years of experience, Rephine has built an enviable reputation as the gold standard in the industry operating from four primary locations: Stevenage in the UK, Barcelona in Spain, India, and Shanghai in China.

He is committed to helping pharmaceutical, biotech, and medical device companies achieve the highest standards in manufacturing and supply chain integrity.

Contact Us

Strengthen Your Assurance Journey

GMP Chapter 22 Adapting to Hybrid Documentation Standards
Explore Gold Solutions